Integrating pharmacogenetics into gemcitabine dosing—time for a change?
Authors:
- Joseph CiccoliniJoseph Ciccolini
- Cédric MercierCMCédric Mercier
- Laetitia DahanLDLaetitia Dahan
- Nicolas AndréNANicolas André
- 8 February 2011
- journal article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 8 (7) , 439-444
Abstract
Increasing the efficacy of anticancer agents and avoiding toxic effects is a critical issue in clinical oncology. Identifying biomarkers that predict clinical outcome would ensure improved patient care. Gemcitabine is widely used to treat various solid tumors as a single agent or in combination with other drugs. The therapeutic index of gemcitabine is narrow, and abnormal pharmacokinetics leading to changes in plasma exposure is a major cause of adverse effects. A number of biomarkers have been proposed to predict efficacy of gemcitabine, focusing on molecular determinants of response identified at the tumor level. Genetic and functional deregulations that affect the disposition of a drug could be the reason for life-threatening adverse effects or treatment failure. In particular, deregulation of cytidine deaminase, the enzyme responsible for detoxification of most nucleotide analogs, should be examined. Identifying and validating biomarkers for pharmacogenetic testing before administration of gemcitabine is a step towards personalized medicine.Keywords
This publication has 70 references indexed in Scilit:
- Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinomaBritish Journal of Cancer, 2010
- Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine TreatmentMolecular & Cellular Proteomics, 2010
- Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphismEuropean Journal of Clinical Pharmacology, 2010
- Single Nucleotide Polymorphisms of Gemcitabine Metabolic Genes and Pancreatic Cancer Survival and Drug ToxicityClinical Cancer Research, 2010
- Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response BiomarkersPLOS ONE, 2009
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic CancerScience, 2009
- Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and PharmacokineticsJournal of Clinical Oncology, 2009
- Phase II Study of Weekly Gemcitabine and Vinorelbine for Children With Recurrent or Refractory Hodgkin's Disease: A Children's Oncology Group ReportJournal of Clinical Oncology, 2009
- Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patientsBritish Journal of Cancer, 2009
- Immunohistochemical and Genetic Evaluation of Deoxycytidine Kinase in Pancreatic Cancer: Relationship to Molecular Mechanisms of Gemcitabine Resistance and SurvivalClinical Cancer Research, 2006